Cancer Family
Hepatobiliary Neoplasm
CI-CAN-00000198Explore in graph →
Non-malignant1,188 active trials17 approved drugs42 evidence items
- NCIt
- C8614
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000198Explore in graph →
Clinical trials
5,266 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02421185 | Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 (Erdafitinib) in Participants With Advanced Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 53 | Janssen Research & Development, LLCINDUSTRY | 3 | Feb 3, 2025 | clinicaltrials |
| NCT04164069 | Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab | completed | Phase 1 | 9 | Anne NoonanOTHER | 1 | Dec 27, 2024 |
| clinicaltrials |
| NCT02143401 | Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors | completed | Phase 1 | 29 | National Cancer Institute (NCI)NIH | 1 | Nov 22, 2024 | clinicaltrials |
| NCT04313868 | GEN2 Directed Cancer Immunotherapy Trial(GEN2) | completed | Phase 1 | 61 | GenVivo, Inc.INDUSTRY | 1 | Nov 6, 2024 | clinicaltrials |
| NCT02325739 | FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression | completed | Phase 1 / Phase 2 | 172 | Novartis PharmaceuticalsINDUSTRY | 11 | Oct 21, 2024 | clinicaltrials |
| NCT03253289 | Meclizine for Hepatocellular Carcinoma(OPTIM) | completed | Phase 1 | 13 | Tannaz ArmaghnayOTHER | 1 | Oct 2, 2024 | clinicaltrials |
| NCT03175679 | Adoptive Transfer of iNKT Cells for Treating Patients With Relapsed/Advanced HCC | completed | Phase 1 | 10 | Beijing YouAn HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04401813 | Efficacy and Safety of IBI310 Combined with Sintilimab in Patients with Advanced Hepatocellular Carcinoma | completed | Phase 1 | 97 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03299946 | Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC) | completed | Phase 1 | 15 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 3, 2024 | clinicaltrials |
| NCT04170556 | Regorafenib Followed by Nivolumab in Patients With Hepatocellular Carcinoma (GOING)(GOING) | completed | Phase 1 / Phase 2 | 69 | Fundacion Clinic per a la Recerca BiomédicaOTHER | 1 | Sep 3, 2024 | clinicaltrials |
| NCT02595866 | Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer | completed | Phase 1 | 58 | National Cancer Institute (NCI)NIH | 1 | Aug 9, 2024 | clinicaltrials |
| NCT02509507 | Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611(MASTERKEY-318) | completed | Phase 1 / Phase 2 | 127 | AmgenINDUSTRY | 9 | Aug 6, 2024 | clinicaltrials |
| NCT02443324 | A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer | completed | Phase 1 | 175 | Eli Lilly and CompanyINDUSTRY | 6 | Jul 31, 2024 | clinicaltrials |
| NCT03752398 | A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)(DUET-3) | completed | Phase 1 | 198 | Xencor, Inc.INDUSTRY | 1 | Jul 5, 2024 | clinicaltrials |
| NCT03418922 | A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular Carcinoma | completed | Phase 1 | 30 | Eisai Co., Ltd.INDUSTRY | 1 | Jun 20, 2024 | clinicaltrials |
| NCT04742959 | Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 203 | TransThera Sciences (Nanjing), Inc.INDUSTRY | 1 | Apr 26, 2024 | clinicaltrials |
| NCT02705105 | Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 / Phase 2 | 114 | Kyowa Kirin, Inc.INDUSTRY | 1 | Apr 25, 2024 | clinicaltrials |
| NCT04444167 | A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 59 | AkesoINDUSTRY | 1 | Apr 25, 2024 | clinicaltrials |
| NCT02508467 | A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma | completed | Phase 1 | 146 | Blueprint Medicines CorporationINDUSTRY | 12 | Apr 12, 2024 | clinicaltrials |
| NCT03329950 | A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies | completed | Phase 1 | 132 | Celldex TherapeuticsINDUSTRY | 1 | Mar 28, 2024 | clinicaltrials |
| NCT02273362 | Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver | completed | Phase 1 / Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Mar 26, 2024 | clinicaltrials |
| NCT03665285 | A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors | completed | Phase 1 / Phase 2 | 109 | NextCure, Inc.INDUSTRY | 1 | Mar 8, 2024 | clinicaltrials |
| NCT00019630 | Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT02168140 | CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma | completed | Phase 1 | 16 | Wake Forest University Health SciencesOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT03893695 | Combination of GT90001 and Nivolumab in Patients With Metastatic Hepatocellular Carcinoma(HCC) | completed | Phase 1 / Phase 2 | 20 | Suzhou Kintor Pharmaceutical Inc,INDUSTRY | 1 | Feb 9, 2024 | clinicaltrials |
| NCT00486356 | Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer | completed | Phase 1 | 46 | University of NebraskaOTHER | 1 | Jan 3, 2024 | clinicaltrials |
| NCT01825603 | ADH-1, Gemcitabine Hydrochloride & Cisplatin in Treating Metastatic Pancreatic or Biliary Tract Cancer | completed | Phase 1 | 17 | University of NebraskaOTHER | 1 | Dec 28, 2023 | clinicaltrials |
| NCT03219268 | A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms | completed | Phase 1 | 277 | MacroGenicsINDUSTRY | 8 | Dec 21, 2023 | clinicaltrials |
| NCT02561273 | Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma | completed | Phase 1 / Phase 2 | 54 | University of NebraskaOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT03006926 | A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular Carcinoma | completed | Phase 1 | 104 | Eisai Co., Ltd.INDUSTRY | 7 | Dec 13, 2023 | clinicaltrials |
| NCT03531320 | Study of D07001-Softgel Capsules in Subjects With Gastrointestinal Cancer in Dose-Escalation Phase and in Subjects With Biliary Tract Cancer in Dose-Expansion Phase | completed | Phase 1 / Phase 2 | 19 | InnoPharmax Inc.INDUSTRY | 1 | Nov 24, 2023 | clinicaltrials |
| NCT01523223 | Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies | completed | Phase 1 | 16 | Robert LowskyOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT02279719 | A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 97 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | Nov 15, 2023 | clinicaltrials |
| NCT02834780 | Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma | completed | Phase 1 | 128 | H3 Biomedicine Inc.INDUSTRY | 11 | Nov 13, 2023 | clinicaltrials |
| NCT03735628 | An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors | completed | Phase 1 | 16 | BayerINDUSTRY | 2 | Oct 6, 2023 | clinicaltrials |
| NCT05930119 | HMPL-453 Food Effect and PPI Study in Healthy Volunteer Study | completed | Phase 1 | 24 | HutchmedINDUSTRY | 1 | Sep 6, 2023 | clinicaltrials |
| NCT03009201 | Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery | completed | Phase 1 | 16 | OHSU Knight Cancer InstituteOTHER | 1 | Aug 16, 2023 | clinicaltrials |
| NCT03602079 | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene | completed | Phase 1 / Phase 2 | 49 | Klus Pharma Inc.INDUSTRY | 1 | Aug 3, 2023 | clinicaltrials |
| NCT04034238 | Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors | completed | Phase 1 | 19 | National Cancer Institute (NCI)NIH | 1 | Aug 1, 2023 | clinicaltrials |
| NCT03347292 | Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC | completed | Phase 1 | 58 | BayerINDUSTRY | 2 | Jul 25, 2023 | clinicaltrials |
| NCT02795429 | Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC | completed | Phase 1 / Phase 2 | 89 | Novartis PharmaceuticalsINDUSTRY | 8 | Jul 3, 2023 | clinicaltrials |
| NCT03829436 | TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers | completed | Phase 1 | 38 | Tempest TherapeuticsINDUSTRY | 1 | Jul 3, 2023 | clinicaltrials |
| NCT05116891 | A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 40 | Cantargia ABINDUSTRY | 2 | Jul 3, 2023 | clinicaltrials |
| NCT04440943 | A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies | completed | Phase 1 | 27 | Celldex TherapeuticsINDUSTRY | 1 | Jun 18, 2023 | clinicaltrials |
| NCT02333188 | Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer | completed | Phase 1 | 50 | University of ChicagoOTHER | 1 | May 31, 2023 | clinicaltrials |
| NCT02351765 | ABC-08: Phase Ib Trial of Acelarin in Combination With Cisplatin in Locally Advanced/ Metastatic Biliary Tract Cancers(ABC-08) | completed | Phase 1 | 21 | The Christie NHS Foundation TrustOTHER | 1 | May 17, 2023 | clinicaltrials |
| NCT03841110 | FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors | completed | Phase 1 | 37 | Fate TherapeuticsINDUSTRY | 1 | May 1, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Feb 3, 2025source: clinicaltrials